NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	The patients with community-acquired pneumonia
Date of first enrollment	16/11/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Garenoxacin 200 mg tablet INN of investigational material : Garenoxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for Investigational material : Oral administration control material(s) Generic name etc : Levofloxacin 500 mg tablet INN of investigational material : Levofloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for Investigational material : Oral administration

Outcome(s)

Primary Outcome	Clinical efficacy, bacteriological responses and safety Clinical efficacy, bacteriological responses and safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	<= 70age old
Gender	Both
Include criteria	(1) Patients with community-acquired pneumonia requiring outpatient or inpatient treatment. (2) Sex: male or female. (3) Age: 18 to 70 years old. (4) Pneumonia patients indicated to oral antibacterial agents. (5) Others.
Exclude criteria	(1)History of hypersensitive reaction to any quinolone antibacterial agents. (2) History of twitch and/or epilepsia or taking antiepileptic agents. (3) Pregnant females, females wishing to become pregnant or being possibly pregnant, and lactating females. (4) Patients with severe infection requiring tretment with injectable antibacterial agents or mechanical ventilator. (5) Others.